The American Journal of Managed Care2d
Ixekizumab Induction Boosts Psoriasis Response, May Lower Drug Survival
A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...
GlobalData on MSN4d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Healthline6d
Why Super Bowl Champ Dallas Goedert Is Raising Awareness About Plaque Psoriasis
Super Bowl LIX champion Dallas Goedert of the Philadelphia Eagles shares his journey with plaque psoriasis. After 20 years of ...
appliedclinicaltrialsonline3d
Five-Year POETYK PSO Trial Results Show Sustained Efficacy, Safety with Sotyktu for Moderate-to-Severe Plaque Psoriasis
Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...
How Do You Know It’s Psoriasis? Here Are The Signs And Symptoms You Should Look For
More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu ...
The American Journal of Managed Care8d
Deucravacitinib Shows Long-Term Safety, Efficacy in Psoriasis Trial
A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.
PMLiVE2d
Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis
Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 ...
Pharmabiz3d
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...